Jul. 05, 2023
Nov. 24, 2022
Aug. 09, 2022
We were selected as one of 9 candidate companies for collaboration with Toshiba Corporation.
Jul. 08, 2022
May. 24, 2022
Apr. 08, 2022
Mar. 02, 2022
Jan. 14, 2022
President Kitamura will be a speaker at LINK-J Member’s Meetup “Drug Discovery vol.1” on January 18.
Jan. 06, 2022
Aug. 04, 2021
We were introduced in “Bio Startups Overview 2021-2022” by Nikkei Biotech, Inc.
Next-generation Peptides Next -generation
Peptide Drug Discovery
Our Mission
By using peptides as drug discovery leads,
that contribute to people’s health and longevity.
We proceed R&D and will provide novel
peptide drug candidates.
Our proprietary technology enables us to conduct R&D of next-generation membrane permeable peptides being different from peptides derived from living organisms.
Merits of Next-generation Peptides
Next-generation Peptides for intracellular drug targets
We have succeeded in acquiring
several membrane-permeable peptides
by using proprietary technology.
Some of these peptides show cell-selectivity against cancer and immune cells.
Support Service for Drug Discovery
Collaborative Business Partners
We seek to provide even higher quality and higher functioning peptides through partnering with the following companies.
| Pharmaceutical companies that we have collaborated with. |
Astellas Pharma Inc. Daiichi Sankyo Company, Limited Shionogi & Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd. Teijin Pharma Limited |
|---|
